Early trials of atrial defect device promising:
This article was originally published in Clinica
Executive Summary
Closing atrial septal defects with a new catheter-based shunt worked in 98% of patients who had successful implants, according to an FDA Phase I trial of the device. The shunt, being developed by Texan firm Custom Medical Devices, was used on 46 patients of an average four years of age. After one year, 45 patients had sufficient closure, with 34 of these having full closure.